How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery?

Chapter

Abstract

Preoperative radiotherapy or chemoradiotherapy (RT/CRT) is used in rectal cancer treatment to decrease the risk of a local recurrence in resectable tumours or to allow radical surgery in non-resectable tumours. In order not to increase the risk of complications after the surgery, surgery should be performed either before the acute radiation-induced toxicity has started, i.e. immediately after short-course RT (2–5 days), or after it has subsided 3–4 weeks after RT/CRT (i.e. 4–8 weeks after the last radiation fraction). Since regression of a rectal adenocarcinoma may take time and there presently is a wish to avoid (major) surgery in many patients, there is a growing interest in prolonging the interval from the RT/CRT to surgery to achieve maximal tumour regression. The pros and cons of delaying surgery are dependent upon the aim of the preoperative RT/CRT.

References

  1. 1.
    Cummings BJ Jr, Rider W, Harwood A et al (1983) Radical external beam radiation therapy for adenocarcinoma of the rectum. Dis Colon Rectum 26:30–36CrossRefPubMedGoogle Scholar
  2. 2.
    Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100(7):933–939CrossRefPubMedGoogle Scholar
  3. 3.
    Glimelius B (2012) Multidisciplinary treatment of patients with rectal cancer: development during the past decades and plans for the future. Ups J Med Sci 117(2):225–236CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Radu C, Berglund Å, Påhlman L, Glimelius B (2008) Short course preoperative radiotherapy with delayed surgery in rectal cancer – a retrospective study. Radiother Oncol 87:343–349CrossRefPubMedGoogle Scholar
  5. 5.
    Papillon J (1982) Rectal and anal cancers. In: Papillon J (ed) Surgical treatment – role of additional therapy: preoperative irradiation. Springer, New York, pp 23–32Google Scholar
  6. 6.
    Cummings BJ (1990) Rectal cancer. In: Dobelbower RR Jr (ed) Gastrointestinal cancer: radiation therapy. Springer, Heidelberg, pp 179–215CrossRefGoogle Scholar
  7. 7.
    Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9):835–844CrossRefPubMedGoogle Scholar
  8. 8.
    Martin ST, Heneghan HM, Winter DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99(7):918–928CrossRefPubMedGoogle Scholar
  9. 9.
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240(4):711–717PubMedPubMedCentralGoogle Scholar
  10. 10.
    Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, Proscurshim I, Sabbagh C, Lynn PB et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88(4):822–828CrossRefPubMedGoogle Scholar
  11. 11.
    Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29(35):4633–4640CrossRefPubMedGoogle Scholar
  12. 12.
    Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516CrossRefPubMedGoogle Scholar
  13. 13.
    Glimelius B, Tiret E, Cervantes A, Arnold D (2013) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi81–vi88CrossRefPubMedGoogle Scholar
  14. 14.
    Valentini V, Glimelius B, Haustermans K, Marijnen CA, Rodel C, Gambacorta MA et al (2014) EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist’s expert review. Radiother Oncol 110:195–198CrossRefPubMedGoogle Scholar
  15. 15.
    Graf W, Dahlberg M, Mazloum-Osman M, Holmberg L, Påhlman L, Glimelius B (1997) Short-term preoperative radiotherapy results in down staging of rectal cancer: a study of 1316 patients. Radiother Oncol 43:133–137CrossRefPubMedGoogle Scholar
  16. 16.
    van den Broek CB, Vermeer TA, Bastiaannet E, Rutten HJ, van de Velde CJ, Marijnen CA (2013) Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients. Eur J Cancer 49:3131–3139CrossRefPubMedGoogle Scholar
  17. 17.
    Hatfield P, Hingorani M, Radhakrishna G, Cooper R, Melcher A, Crellin A et al (2009) Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 92(2):210–214CrossRefPubMedGoogle Scholar
  18. 18.
    Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A (2012) Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 99(4):577–583CrossRefPubMedGoogle Scholar
  19. 19.
    Pettersson D, Cedermark B, Holm T, Radu C, Pahlman L, Glimelius B et al (2010) Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 97(4):580–587CrossRefPubMedGoogle Scholar
  20. 20.
    Fokstuen T, Holm T, Glimelius B (2009) Postoperative morbidity and mortality in relation to leukocyte counts and time to surgery after short-course preoperative radiotherapy for rectal cancer. Radiother Oncol 93(2):293–297CrossRefPubMedGoogle Scholar
  21. 21.
    Marijnen CAM, Kapiteijn E, van de Velde CJ, Martijn H, Steup WH, Wiggers T et al (2002) Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 3:817–825CrossRefGoogle Scholar
  22. 22.
    Hartley A, Giridharan S, Srihari N, McConkey C, Geh JI (2003) Impaired postoperative neutrophil leucocytosis and acute complications following short course preoperative radiotherapy for operable rectal cancer. Eur J Surg Oncol 29(2):155–157CrossRefPubMedGoogle Scholar
  23. 23.
    Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A (2013) Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III trial. Br J Surg 100(7):969–975CrossRefPubMedGoogle Scholar
  24. 24.
    Pach R, Kulig J, Richter P, Gach T, Szura M, Kowalska T (2012) Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer–treatment results at 5-year follow-up. Langenbeck's Arch Surg 397(5):801–807CrossRefGoogle Scholar
  25. 25.
    Pettersson D, Lorinc E, Holm T, Iversen H, Cedermark B, Glimelius B et al (2015) Tumour regression in the randomized Stockholm III trial of radiotherapy regimens for rectal cancer. Br J Surg 102(8):972–978CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Veenhof AA, Bloemena E, Engel AF, van der Peet DL, Meijer OW, Cuesta MA (2009) The relationship of histological tumor regression grade (TRG) and two different time intervals to surgery following radiation therapy for locally advanced rectal cancer. Int J Color Dis 24(9):1091–1096CrossRefGoogle Scholar
  27. 27.
    Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C et al (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346CrossRefPubMedGoogle Scholar
  28. 28.
    Petrelli F, Sgroi G, Sarti E, Barni S (2013) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 263(3):458–464CrossRefGoogle Scholar
  29. 29.
    Saglam S, Bugra D, Saglam EK, Asoglu O, Balik E, Yamaner S et al (2014) Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. J Gastrointest Oncol 5(1):9–17PubMedPubMedCentralGoogle Scholar
  30. 30.
    Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C et al (2016) Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. doi: 10.1200/JCO.2016.67.6049
  31. 31.
    Evans J, Bhoday J, Sizer B, Tekkis P, Swift R, Perez R, et al (2016) Results of a prospective randomised control 6 vs 12 trial: is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? ESMO Abstr 4520Google Scholar
  32. 32.
    Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A (2013) Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 85(1):74–80CrossRefPubMedGoogle Scholar
  33. 33.
    Kerr SF, Norton S, Glynne-Jones R (2008) Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg 95(12):1534–1540CrossRefPubMedGoogle Scholar
  34. 34.
    Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M (2008) An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 15(10):2661–2667CrossRefPubMedGoogle Scholar
  35. 35.
    Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS et al (2008) Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 248(2):243–251CrossRefPubMedGoogle Scholar
  36. 36.
    Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17(8):2396–2402CrossRefPubMedGoogle Scholar
  37. 37.
    Sprawka A, Pietrzak L, Garmol D, Tyc-Szczepaniak D, Kepka L, Bujko K (2013) Definitive radical external beam radiotherapy for rectal cancer: evaluation of local effectiveness and risk of late small bowel damage. Acta Oncol 52(4):816–823CrossRefPubMedGoogle Scholar
  38. 38.
    Gerard JP, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R et al (2004) Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol 22(12):2404–2409CrossRefPubMedGoogle Scholar
  39. 39.
    Ortholan C, Romestaing P, Chapet O, Gerard JP (2012) Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int J Radiat Oncol Biol Phys 83(2):e165–e171CrossRefPubMedGoogle Scholar
  40. 40.
    Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR (2012) Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 84(4):949–954CrossRefPubMedGoogle Scholar
  41. 41.
    Hall MD, Schultheiss TE, Smith DD, Fakih MG, Wong JYC, Chen YJ (2016) Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol 55:1392–1399CrossRefPubMedGoogle Scholar
  42. 42.
    Glimelius B (2016) What is most relevant in preoperative rectal cancer chemoradiotherapy – the chemotherapy, the radiation dose or the timing to surgery? Acta Oncol 55(12):1381–1385CrossRefPubMedGoogle Scholar
  43. 43.
    Glimelius B (2017) On a prolonged interval between rectal cancer (chemo) radiotherapy and surgery. Ups J Med Sci 122(1):1–10CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon & Rectum 53(12):1692–1698CrossRefGoogle Scholar
  45. 45.
    Habr-Gama A, Gama-Rodrigues J, Perez RO (2013) Is tailoring treatment of rectal cancer the only true benefit of long-course neoadjuvant chemoradiation? Dis Colon Rectum 56(2):264–266CrossRefPubMedGoogle Scholar
  46. 46.
    Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM (2011) Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254(1):97–102CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Radu C, Norrlid O, Braendengen M, Hansson K, Isacsson U, Glimelius B (2013) Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta Oncol 52(3):528–537CrossRefPubMedGoogle Scholar
  48. 48.
    Perez RO, Habr-Gama A, Sao Juliao GP, Gama-Rodrigues J, Sousa AH Jr, Campos FG et al (2012) Optimal timing for assessment of tumor response to neoadjuvant chemoradiation in patients with rectal cancer: do all patients benefit from waiting longer than 6 weeks? Int J Radiat Oncol Biol Phys 84(5):1159–1165CrossRefPubMedGoogle Scholar
  49. 49.
    Withers HR, Haustermans K (2004) Where next with preoperative radiation therapy for rectal cancer? Int J Radiat Oncol Biol Phys 58(2):597–602CrossRefPubMedGoogle Scholar
  50. 50.
    Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski B et al (2002) How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 54(1):229–236CrossRefPubMedGoogle Scholar
  51. 51.
    Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(2):200–207CrossRefPubMedGoogle Scholar
  52. 52.
    Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M (2015) Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery +/− a fluoropyrimidine and surgery + a fluoropyrimidine +/− oxaliplatin. Eur J Surg Oncol 41(6):713–723CrossRefPubMedGoogle Scholar
  53. 53.
    Nilsson PJ, van Etten B, Hospers GAP, Påhlman L, van de Velde CJH, Beets-Tan RGH et al (2013) Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial. BMC Cancer 13:279CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J et al (2016) Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27(5):834–842CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.Department of Surgical ScienceUppsala UniversityUppsalaSweden
  2. 2.Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical OncologyUppsala UniversityUppsalaSweden

Personalised recommendations